Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California. more
Time Frame | CDXC | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.26% | 0.67% | 0.49% |
1-Month Return | 32.58% | 0.26% | 5.96% |
3-Month Return | 132.01% | -6.21% | 9.35% |
6-Month Return | 159.73% | 1.69% | 14.4% |
1-Year Return | 443.57% | 11.41% | 32.23% |
3-Year Return | 74.94% | 12.87% | 33.15% |
5-Year Return | 113.76% | 48.89% | 95.23% |
10-Year Return | 139.31% | 109.26% | 191.11% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 46.29M | 59.26M | 67.45M | 72.05M | 83.57M | [{"date":"2019-12-31","value":55.39,"profit":true},{"date":"2020-12-31","value":70.91,"profit":true},{"date":"2021-12-31","value":80.71,"profit":true},{"date":"2022-12-31","value":86.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 20.52M | 23.98M | 25.96M | 29.25M | 32.79M | [{"date":"2019-12-31","value":62.59,"profit":true},{"date":"2020-12-31","value":73.14,"profit":true},{"date":"2021-12-31","value":79.17,"profit":true},{"date":"2022-12-31","value":89.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 25.77M | 35.27M | 41.49M | 42.80M | 50.78M | [{"date":"2019-12-31","value":50.75,"profit":true},{"date":"2020-12-31","value":69.46,"profit":true},{"date":"2021-12-31","value":81.71,"profit":true},{"date":"2022-12-31","value":84.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 55.67% | 59.53% | 61.51% | 59.40% | 60.76% | [{"date":"2019-12-31","value":90.5,"profit":true},{"date":"2020-12-31","value":96.77,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.56,"profit":true},{"date":"2023-12-31","value":98.78,"profit":true}] |
Operating Expenses | 57.07M | 55.13M | 68.56M | 61.42M | 56.38M | [{"date":"2019-12-31","value":83.24,"profit":true},{"date":"2020-12-31","value":80.4,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":89.59,"profit":true},{"date":"2023-12-31","value":82.23,"profit":true}] |
Operating Income | (31.30M) | (19.85M) | (27.07M) | (18.63M) | (5.60M) | [{"date":"2019-12-31","value":-3130000000,"profit":false},{"date":"2020-12-31","value":-1985400000,"profit":false},{"date":"2021-12-31","value":-2707300000,"profit":false},{"date":"2022-12-31","value":-1862800000,"profit":false},{"date":"2023-12-31","value":-559900000,"profit":false}] |
Total Non-Operating Income/Expense | (1.69M) | (142.00K) | (110.00K) | 2.09M | 1.07M | [{"date":"2019-12-31","value":-81.01,"profit":false},{"date":"2020-12-31","value":-6.79,"profit":false},{"date":"2021-12-31","value":-5.26,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":50.98,"profit":true}] |
Pre-Tax Income | (32.15M) | (19.93M) | (27.13M) | (16.54M) | (4.94M) | [{"date":"2019-12-31","value":-3214700000,"profit":false},{"date":"2020-12-31","value":-1992500000,"profit":false},{"date":"2021-12-31","value":-2712800000,"profit":false},{"date":"2022-12-31","value":-1654000000,"profit":false},{"date":"2023-12-31","value":-493800000,"profit":false}] |
Income Taxes | (676.00K) | (1.44M) | (1.57M) | (2.09M) | 1.54M | [{"date":"2019-12-31","value":-43.98,"profit":false},{"date":"2020-12-31","value":-93.81,"profit":false},{"date":"2021-12-31","value":-102.21,"profit":false},{"date":"2022-12-31","value":-136.03,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (31.47M) | (18.48M) | (25.56M) | (14.45M) | (6.48M) | [{"date":"2019-12-31","value":-3147100000,"profit":false},{"date":"2020-12-31","value":-1848300000,"profit":false},{"date":"2021-12-31","value":-2555700000,"profit":false},{"date":"2022-12-31","value":-1444900000,"profit":false},{"date":"2023-12-31","value":-647510500,"profit":false}] |
Income From Continuous Operations | (32.15M) | (19.93M) | (27.13M) | (18.63M) | (6.47M) | [{"date":"2019-12-31","value":-3214700000,"profit":false},{"date":"2020-12-31","value":-1992500000,"profit":false},{"date":"2021-12-31","value":-2712800000,"profit":false},{"date":"2022-12-31","value":-1862500000,"profit":false},{"date":"2023-12-31","value":-647000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (31.47M) | (18.48M) | (25.56M) | (14.45M) | (4.94M) | [{"date":"2019-12-31","value":-3147100000,"profit":false},{"date":"2020-12-31","value":-1848300000,"profit":false},{"date":"2021-12-31","value":-2555700000,"profit":false},{"date":"2022-12-31","value":-1444900000,"profit":false},{"date":"2023-12-31","value":-493800000,"profit":false}] |
EPS (Diluted) | (0.55) | (0.33) | (0.41) | (0.26) | (0.07) | [{"date":"2019-12-31","value":-55,"profit":false},{"date":"2020-12-31","value":-33,"profit":false},{"date":"2021-12-31","value":-41,"profit":false},{"date":"2022-12-31","value":-26,"profit":false},{"date":"2023-12-31","value":-6.85,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CDXC | |
---|---|
Cash Ratio | 1.83 |
Current Ratio | 2.95 |
Quick Ratio | 2.35 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CDXC | |
---|---|
ROA (LTM) | 0.51% |
ROE (LTM) | 4.82% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CDXC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.39 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.61 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CDXC | |
---|---|
Trailing PE | 380.50 |
Forward PE | 58.14 |
P/S (TTM) | 6.34 |
P/B | 16.80 |
Price/FCF | 168 |
EV/R | 5.98 |
EV/Ebitda | 281.66 |
PEG | NM |
Chromadex Corp (CDXC) share price today is $7.61
Yes, Indians can buy shares of Chromadex Corp (CDXC) on Vested. To buy Chromadex Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CDXC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Chromadex Corp (CDXC) via the Vested app. You can start investing in Chromadex Corp (CDXC) with a minimum investment of $1.
You can invest in shares of Chromadex Corp (CDXC) via Vested in three simple steps:
The 52-week high price of Chromadex Corp (CDXC) is $7.97. The 52-week low price of Chromadex Corp (CDXC) is $1.32.
The price-to-earnings (P/E) ratio of Chromadex Corp (CDXC) is 378
The price-to-book (P/B) ratio of Chromadex Corp (CDXC) is 16.80
The dividend yield of Chromadex Corp (CDXC) is 0.00%
The market capitalization of Chromadex Corp (CDXC) is $577.46M
The stock symbol (or ticker) of Chromadex Corp is CDXC